Evidence map›Paper›PMID 31754026›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

Anupriya Agarwal, William J Bolosky, David B Wilson, Christopher A Eide, Susan B Olson, Guang Fan, Brian J Druker

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Epigenetic regulation of cancer stemness.Signal transduction and targeted therapy · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Anupriya AgarwalDivision of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239; agarwala@ohsu.edu drukerb@ohsu.edu.
William J BoloskySystems Research Group, Microsoft Research, Redmond, WA 98052.
David B WilsonDepartment of Mathematics, University of Washington, Seattle, WA 98195.
Christopher A EideDivision of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239.
Susan B OlsonDepartment of Molecular and Medical Genetics, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239.
Guang FanDepartment of Pathology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239.
Brian J DrukerDivision of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239; agarwala@ohsu.edu drukerb@ohsu.edu.
Oregon Health & Science University · USHoward Hughes Medical Institute · USMicrosoft (United States) · USUniversity of Washington · US

Funding

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AMLU54CA224019 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Jeffrey Wallace Tyner · 2017 to 2026
$13.9M
Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic MalignanciesU01CA217862 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J, TYNER, JEFFREY WALLACE · 2017 to 2021
$5.3M
Studying drug resistance in AML and PDAC using a novel heterotypic 3D organoid modelR01CA229875 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI AGARWAL, ANUPRIYA · 2019 to 2023
$1.6M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA229875NCI NIH HHS U01 CA217862NCI NIH HHS U54 CA224019
6 · The paper itself

Abstract

Hematopoiesis, the formation of blood cells, involves the hierarchical differentiation of immature blast cells into mature, functional cell types and lineages of the immune system. Hematopoietic stem cells precisely regulate self-renewal versus differentiation to balance the production of blood cells and maintenance of the stem cell pool. The canonical view of acute myeloid leukemia (AML) is that it results from a combination of molecular events in a hematopoietic stem cell that block differentiation and drive proliferation. These events result in the accumulation of primitive hematopoietic blast cells in the blood and bone marrow. We used mathematical modeling to determine the impact of varying differentiation rates on myeloblastic accumulation. Our model shows that, instead of the commonly held belief that AML results from a complete block of differentiation of the hematopoietic stem cell, even a slight skewing of the fraction of cells that differentiate would produce an accumulation of blasts. We confirmed this model by interphase fluorescent in situ hybridization (FISH) and sequencing of purified cell populations from patients with AML, which showed that different leukemia-causing molecular abnormalities typically thought to block differentiation were consistently present in mature myeloid cells such as neutrophils and monocytes at similar levels to those in immature myeloid cells. These findings suggest reduced or skewed, rather than blocked, differentiation is responsible for the development of AML. Approaches that restore normal regulation of hematopoiesis could be effective treatment strategies.

Indexed as

Models, BiologicalAdolescentAdultAgedBlast CrisisCell DeathCell DifferentiationFemaleGene Expression Regulation, LeukemicHematopoiesisHematopoietic Stem CellsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyeloid CellsTranscription FactorsAMLdifferentiation blockmathematical model

Identifiers

PMID31754026
PMCPMC6900505
OpenAlexW2991222749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.